Conley, RR, Ascher-Svanum, H, Zhu, B, Faries, DE, Kinon, BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res
2007; 90: 186–97.
Hafner, H, Maurer, K, Trendler, G, van der Heiden, W, Schmidt, M, Konnecke, R. Schizophrenia and depression: challenging the paradigm of two separate diseases – a controlled study of schizophrenia, depression and healthy controls. Schizophr Res
2005; 77: 11–24.
Buckley, PF, Miller, BJ, Lehrer, DS, Castle, DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull
2009; 35: 383–402.
Whitehead, C, Moss, S, Cardno, A, Lewis, G. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev
2002; 2: CD002305.
Addington, J, Duchak, V. Reasons for substance use in schizophrenia. Acta Psychiatr Scand
1997; 96: 329–33.
Reine, G, Lancon, C, Di Tucci, S, Sapin, C, Auquier, P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand
2003; 108: 297–303.
Saha, S, Chant, D, McGrath, J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?
Arch Gen Psychiatry
2007; 64: 1123–31.
Barnes, TR, Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol
2011; 25: 567–620.
National Insitute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Treatment and Management.
. NICE, 2014.
Siris, SG, Addington, D, Azorin, JM, Falloon, IR, Gerlach, J, Hirsch, S, et al. Depression in schizophrenia: recognition and management in the USA. Schizophr Res
2001; 47: 185–97.
Ballon, J, Stroup, TS. Polypharmacy for schizophrenia. Curr Opin Psychiatry
2013; 26: 208–13.
Upthegrove, R, Marwaha, S, Birchwood, M. Depression and schizophrenia: cause, consequence or trans-diagnostic issue?
2017; 43; 240–4.
Heifer, B, Samara, MT, Huhn, M, Klupp, E, Leucht, C, Zhu, Y, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry
2017; 173: 876–86.
Higgins, JP, Green, S. Cochrane Handbook for Systematic Reviews of Interventions.
John Wiley & Sons, 2011.
Collins, AA, Remington, G, Coulter, K, Birkett, K. Depression in schizophrenia: a comparison of three measures. Schizophr Res
1996; 20: 205–9.
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (4th edn) . APA, 1994.
Spitzer, RL, Endicott, J, Robins, E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry
1978; 35: 773–82.
Kurland, AA, Nagaraju, A. Viloxazine and the depressed schizophrenic – methodological issues. J Clin Pharmacol
1981; 21: 37–41.
Berk, M, Gama, CS, Sundram, S, Hustig, H, Koopowitz, L, D'Souza, R, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol
2009; 24: 233–8.
Johnson, DA. Studies of depressive symptoms in schizophrenia. Br J Psychiatry
1981; 139: 89–101.
Singh, AN, Saxena, B, Nelson, HL. A controlled clinical study of trazodone in chronic schizophrenic patients with pronounced depressive symptomatology. Curr Ther Res
1978; 23: 485–501.
Omranifard, V, Hosseini, GM, Sharbafchi, MR, Maracy, M, Ghasemi, F, Aminoroaia, M. Sertraline as an add-on treatment for depressive symptoms in stable schizophrenia: a double-blind randomized controlled trial. J Res Med Sci
2012; 17: S1–7.
Addington, D, Addington, J, Patten, S, Remington, G, Moamai, J, Labelle, A, et al. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol
2002; 22: 20–5.
Zisook, S, Kasckow, JW, Golshan, S, Fellows, I, Solorzano, E, Lehman, D, et al. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry
2009; 70: 562–71.
Mulholland, C, Lynch, G, King, DJ, Cooper, SJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J Psychopharmacol
2003; 17: 107–12.
Prusoff, BA, Williams, DH, Weissman, MM, Astrachan, BM. Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine. Arch Gen Psychiatry
1979; 36: 569–75.
Hogarty, GE, McEvoy, JP, Ulrich, RF, DiBarry, AL, Bartone, P, Cooley, S, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry
1995; 52: 29.
Siris, S, Pollack, S, Bermanzohn, P, Stronger, R. Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia. Schizophr Res
2000; 44: 187–92.
Izakova, L, Andre, I, Halaris, A. Combination therapy or monotherapy for the depressed type of schizoaffective disorder. Neuropsychiatr Dis Treat
Berk, M, Ichim, C, Brook, S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol
2001; 16: 87–92.
Kasckow, JW, Mohamed, S, Thallasinos, A, Carroll, B, Zisook, S, Jeste, DV. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. Int J Geriatr Psychiatry
2001; 16: 1163–7.
Hinkelmann, K, Yassouridis, A, Kellner, M, Jahn, H, Wiedemann, K, Raedler, TJ. No effects of antidepressants on negative symptoms in schizophrenia. J Clin Psychopharmacol
2013; 33: 686–90.
Niitsu, T, Fujisaki, M, Shiina, A, Yoshida, T, Hasegawa, T, Kanahara, N, et al. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol
2012; 32: 593–601.
Mico, U, Bruno, A, Pandolfo, G, Romeo, VM, Mallamace, D, D'Arrigo, C, et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol
2011; 26: 303–10.
Terevnikov, V, Stenberg, J-H, Tiihonen, J, Joffe, M, Burkin, M, Tchoukhine, E, et al. Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. Hum Psychopharmacol
2011; 26: 188–93.
Taiminen, TJ, Syvälahti, E, Saarijärvi, S, Niemi, H, Lehto, H, Ahola, V, et al. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int Clin Psychopharmacol
1997; 12: 31–5.
Upthegrove, R, Ross, K, Brunet, K, McCollum, R, Jones, L. Depression in first episode psychosis: the role of subordination and shame. Psychiatry Res
2014; 217: 177–84.
Chavda, N, Kantharia, N. Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression. J Pharmacol Pharmacother
2011; 2: 11–6.
Arroll, B, Elley, CR, Fishman, T, Goodyear-Smith, FA, Kenealy, T, Blashki, G, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev
2009; 3: cd007954.
Gardsjord, ES, Romm, KL, Friis, S, Barder, HE, Evensen, J, Haahr, U, et al. Subjective quality of life in first-episode psychosis. A ten year follow-up study. Schizophr Res
2016; 172: 23–8.
NHS England. Guidance to Support the Introduction of Access and waiting Time Standards for Mental Health Services in 2015/16.
NHS England, 2015.
Jauhar, S, McKenna, PJ, Radua, J, Fung, E, Salvador, R, Laws, KR. Cognitive–behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry
2014; 204: 20–9.
Hazell, CM, Hayward, M, Cavanagh, K, Strauss, C. A systematic review and meta-analysis of low intensity CBT for psychosis. Clinical Psychol Rev
2016; 45: 183–92.
Tiihonen, J, Suokas, JT, Suvisaari, JM, Haukka, J, Korhonen, P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry
2012; 69: 476–83.
Nutt, DJ, Sharpe, M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol
2008; 22: 3–6.
Klingberg, S, Herrlich, J, Wiedemann, G, Wolwer, W, Meisner, C, Engel, C, et al. Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study. J Nerv Ment Dis
2012; 200: 569–76.
Taylor, M, Perera, U. NICE CG178 Psychosis and Schizophrenia in Adults: Treatment and Management – an evidence-based guideline?
Br J Psychiatry
2015; 206: 357–9.
Upthegrove, R, Birchwood, M, Ross, K, Brunett, K, McCollum, R, Jones, L. The evolution of depression and suicidality in first episode psychosis. Acta Psychiatr Scand
2010; 122: 211–8.
Sandhu, A, Ives, J, Birchwood, M, Upthegrove, R. The subjective experience and phenomenology of depression following first episode psychosis: a qualitative study using photo-elicitation. J Affect Disord
2013; 149: 166–74.